LONDON (Alliance News) - Medical technology company ANGLE PLC on Monday said the results of the ongoing work on its Parsortix liquid biopsy system have provided evidence supporting its use in detecting and assessing prostate cancer.
Patient data from tests conducted by Barts Cancer Institute in the UK has suggested Parsortix can be used both to detect prostate cancer and to assess the aggressiveness of the disease, all by means of a blood test.
ANGLE said the fact this can be achieved using only a simple blood test is key, as it means men with low-level disease could avoid having to undertake "unnecessary and potentially harmful" solid biopsy and surgical intervention.
"These are highly encouraging results for the use of the Parsortix system for a clinical application in prostate cancer. This opens the potential of another highly differentiated liquid biopsy application for Parsortix in a key area of medical need, which cannot be addressed by ctDNA or antibody-based CTC systems, where there is the potential to improve patient care and at the same time reduce healthcare costs," said ANGLE Chief Executive Andrew Newland.
ANGLE shares were up 11% to 78.25 pence early Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Angle (AGL)